Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12

Bone Marrow Transplantation

Volumn 18, Issue 1, 1996, Pages 63-71

  Wong, E K ^a,e   Eaves, C ^a,d,e,f   Klingemann, H G ^a,b,c,d,e,g  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b Leukemia Bone Marrow Transplant Program of British Columbia   (Canada)

^c Division of Hematology   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e Pathology and Laboratory Medicine   (Canada)

^f Provincial Medical Genetics Program   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Acute myelogenous leukemia; Interleukin 2; Purging

Indexed keywords

ANTIBIOTIC G 418; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 7; NEOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD CELL; BONE MARROW; BONE MARROW CELL; BONE MARROW PURGING; CELL MEDIATED CYTOTOXICITY; CELL STRAIN K 562; CHROMIUM 51 RELEASE; CONTROLLED STUDY; CYTOLYSIS; DAUDI CELL; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; LEUKEMIA; NATURAL KILLER CELL; PRIORITY JOURNAL;

BLOOD CELLS; BLOOD PRESERVATION; BONE MARROW; BONE MARROW CELLS; CELLS, CULTURED; CRYOPRESERVATION; CYTOTOXICITY TESTS, IMMUNOLOGIC; HUMANS; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKIN-7; KILLER CELLS, NATURAL; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0029782043     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lowenberg B, Verdonck LJ, Dekker AW et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J Clin Oncol 1990; 8: 287-294.
2. Gorin NC, Labopin M, Meloni G et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia 1991; 5: 896-904.
3. McMillan AK, Goldstone AH, Linch DC et al. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 1990; 76: 480-488.
4. Korbling M, Fliedner TM, Holle R et al. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: Influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant 1991; 7: 343-349.
5. Sanz MA, De la Rubia J, Sanz GF et al. Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. J Clin Oncol 1993; 11: 1661-1667.
6. Gale RP, Horowitz MM, Ash RC et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120: 646-652.
7. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. New Engl J Med 1979; 300: 1068-1073.
8. Gale RP, Champlin RE. How does bone marrow transplantation cure leukaemia? Lancet 1984; 2: 28-30.
9. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
10. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. lancet 1993; 341: 85-86.
11. Coulombel L, Eaves C, Kalousek D et al. Long-term marrow culture of cells from patients with acute myelogenous leukemia. Selection in favor of normal phenotypes in some but not all cases. J Clin Invest 1985; 75: 961-969.
12. Udomsakdi C, Eaves CJ, Swolin B et al. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci USA 1992; 89: 6192-6196.
13. Charak BS, Brynes RK, Groshen S et al. Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 1990; 76: 2187-2190.
14. Long GS, Hiserodt JC, Harnaha JB, Cramer DV. Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation. Transplantation 1988; 46: 433-438.
15. Gong J, Thacker JD, Klingemann H-G. Use of IL-2 activated bone marrow to eliminate minimal residual acute myeloid leukemia prior to autologous marrow transplantation. Exp Hematol 1992; 20: 728 (abstr.).
16. Klingemann H-G, Deal H, Reid D, Eaves CJ. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Exp Hematol 1993; 21: 1263-1270.
17. Klingemann H-G, Neerunjun J, Schwulera U, Ziltener HJ. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation and cytokine production. Leukemia 1993; 7: 1389-1393.
18. Klingemann H-G, Eaves CJ, Barnett MJ et al. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 1994; 14: 389-396.
19. Klingemann H-G, Eaves CJ, Barnett MJ et al. Autologous transplantation in patients with acute myeloid leukemia in first remission with IL-2-cultured marrow or peripheral blood stem cells followed by in vivo IL-2. Onkologie 1995; 18: 44-47.
20. Alderson MR, Sassenfeld HM, Widmer MB. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J Exp Med 1990; 172: 577-587.
21. Rossi AR, Pericle F, Rashleigh S et al. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994; 83: 1323-1328.
22. Klingemann H-G, Wong E. Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells. Cancer Immunol Immunother 1991; 33: 395-397.
23. Wong TK, Neumann E. Electric field mediated gene transfer. Biochem Biophys Res Commun 1982; 107: 584-587.
24. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
25. Keever CA, Pekle K, Gazzola MV et al. NK and LAK activities from human marrow progenitors. Cell Immunol 1990; 126: 211-226.
26. O'Shea J, Ortaldo JR. The biology of natural killer cells. In: Lewis CE, McGee JO'D (eds). The Natural Killer Cell. Oxford University Press: Oxford, p 2, 1992.
27. Gately MK, Desai BB, Wolitzky AG et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991; 147: 874-882.
28. Cesano A, Visonneau S, Clark SC, Santoli D. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12. J Immunol 1993; 151: 2943-2957.
29. McCulloch EA, Minden MD, Miyauchi J et al. Stem cell renewal and differentiation in acute myeloblastic leukaemia. J Cell Sci [Suppl] 1988; 10: 267-281.
30. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
31. Chang J, Morgenstern GR, Coutinho LH et al. The use of bone marrow cells grown in long-term culture for autologous bone marrow transplantation in acute myeloid leukaemia: an update. Bone Marrow Transplant 1989; 4: 5-9.
32. Neubauer MA, Benyunes MC, Thompson JA et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1994; 13: 311-316.